Cell Biotech Co

Cell Biotech Co OCF Margin

The Operating Cash Flow Margin of Cell Biotech Co (049960.KQ) as of Nov 19, 2026 is 20.91 %. In the previous year, Operating Cash Flow Margin was 38.60 % — a change of -45.83% (lower).

OCF Margin

20.91 %

YoY

-45.83%

Last updated:

Operating Cash Flow Margin of Cell Biotech Co is 2025 20.91 % . Operating Cash Flow Margin of Cell Biotech Co was 2024 38.60 % . It decreases by -45.83% lower compared to the previous year.

The Cell Biotech Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
22.35 KRW
Jan 1, 2019
22.26 KRW
Jan 1, 2020
20.98 KRW
Jan 1, 2021
31.77 KRW
Jan 1, 2022
25.36 KRW
Jan 1, 2023
14.53 KRW
Jan 1, 2024
38.60 KRW
Jan 1, 2025
20.91 KRW
The Cell Biotech Co OCF Margin history
YEAROCF MarginYoY
20.91 %-45.83%
38.60 %+165.66%
14.53 %-42.71%
25.36 %-20.18%
31.77 %+51.42%
20.98 %-5.75%
22.26 %-0.38%
22.35 %-39.44%
36.90 %+19.51%
30.87 %-16.19%
36.84 %+51.58%
24.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Operating Cash Flow Margin of Cell Biotech Co is 20.91 % in 2025.

Operating Cash Flow Margin of Cell Biotech Co changed from 38.60 % to 20.91 %, representing a -45.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Cell Biotech Co

All Key Metrics — Cell Biotech Co